The Controlled Substances Act shapes federal drug policy, classifying substances into schedules and guiding enforcement by the DEA and FDA.
The U.S. Department of Justice has reached a settlement with Walmart over alleged violations of the Controlled Substances Act tied to opioid dispensing. The company has not admitted liability. The settlement resolves claims dating back to 2013, with previous related actions already settled in 2022. Walmart shares edged higher as the deal was announced today.